Search
01/10/2024
Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC
Jones, DR, Wakelee, H, Spicer, JD, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Wang, W, Chen, H, Dooms, C, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Huang, HC, Novello, S, Jensen, E, Keller, SM, Samkari, A, Kalhor, N. Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway
Majem, M, Sullivan, IG, Torrego, A, Surrallés, J, Purdy, J, Carmona, MA, Dunsford, H, Wubs, M. An Evidence-Driven Approach to Optimizing Clinical, Operational, And Economic Value in the Lung Cancer Care Pathway. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC
Piedra, A, Guinart-Cuadra, A, Mulet, M, Zamora, C, Alejandre, J, Martínez-Recio, S, Barba, A, Sullivan, I, Serra-López, J, Isla, D, Arriola, E, Paz-Ares, L, Diz, MP, Moreno, AL, Callejo, A, Vidal, S, Majem, M. Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial)
Provencio, M, Nadal, E, Insa, A, Campelo, MRG, Calvo, V, Palmero, R, Lázaro, M, Dómine, M, Majem, M, Rodríguez-Abreu, D, Martínez-Martí, A, Carpeño, JDC, Cobo, M, Bernabé, R, Viñolas, N, Barneto, I, Viteri, S, Cruz-Bermudez, A, Romero, A, Massutí, B. Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial). Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study
Garcia-Campelo, R, Gómez, MD, de Castro, J, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Dols, MC. Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials
Martínez-Toledo, C, Sierra, B, Molina-Alejandre, M, Casarrubios, M, Calvo, V, Nadal, E, Campelo, MRG, Martínez-Martí, A, Garrido, A, Massutí, B, Insa, A, De Castro, J, Dóomine, M, González-Larriba, JL, Majem, M, Ponce, S, Barneto, I, Aguilar, A, Martín-López, J, Provencio, M, Cruz-Bermúdez, A. TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update
Spigel, DR, Ahn, MJ, Majem, M, Rodríguez, LM, Lee, KH, Carcereny, E, Hernández, AA, Insa, A, Cho, EK, Besse, B, Rha, SY, Weiss, J, D'Arcangelo, M, Im, SA, Kim, SW, Carneiro, BA, Gadgeel, SM, Mitchell, P, Asare, JM, Gainer, SD, Achour, I, Subramaniam, DS, Felip, E. Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
Nguyen, D, Besse, B, Cho, BC, Lee, SH, Lee, KH, Lu, S, Cheng, Y, Yao, Y, Girard, N, Lin, CC, Felip, E, Aguilar, A, Charoentum, C, Cruz, FJSM, Majem, M, Lim, CS, Akamatsu, H, Hayashi, H, Yang, JCH, Kowalyszyn, R, Tiscoski, K, Franke, F, Ponomarenko, D, Arslan, C, Forster, M, Urban, D, Misch, D, Delmonte, A, Montes, LVG, Gadgeel, SM, Cruz-Correa, M, Peguero, J, Rousey, S, Gaffar, Y, Owen, S, Schuchard, J, Diels, J, Sermon, J, Sun, T, Ennis, M, Fennema, E, Daksh, M, Sethi, S, Bauml, JM, Campelo, MRG. Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
From the Rare to the Extraordinary Pancreatic Serous Cystadenocarcinoma With Hepatic and Bone Dissemination: A Letter to the Editor
Cardozo, A, Lleida, R, Szafranska, J, Piñol, D, Serdà, P, Martin-Cullell, B, Manrique, A, López-Bravo, D, Mateo, FJ. From the Rare to the Extraordinary Pancreatic Serous Cystadenocarcinoma With Hepatic and Bone Dissemination: A Letter to the Editor. PANCREAS. 2024; 53(9)DOI:10.1097/MPA.0000000000002362. PMID:39250559. IF:1.700(Q3/8D).
01/10/2024
RET overexpression in absence of fusions or mutations associates with sensitivity to RET TKIs in lung cancer
Sullivan, I, Aguado, C, Baroni, M, Teixeira, S, Bertran, J, Giménez, A, Aldeguer, E, Román, R, Reguart, N, López, L, Cavagna, R, Marín, E, García, B, Rodriguez, S, Rosell, R, Ferro, L, Chae, Y, Reis, R, Molina, MA. RET overexpression in absence of fusions or mutations associates with sensitivity to RET TKIs in lung cancer. EUROPEAN JOURNAL OF CANCER. 2024; 211DOI:10.1016/j.ejca.2024.114800. PMID:. IF:7.100(Q1/2D).
01/10/2024
Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil
Esquirol, A, Pascual, MJ, Montoro, J, Piñana, JL, Ferrà, C, Herruzo, B, Garcia-Cadenas, I, Balaguer, A, Perez, A, Huguet, M, Redondo, S, Villalba, M, Hernandez-Boluda, JC, Chorao, P, Hernani, R, Sanz, J, Solano, C, Sierra, J, Martino, R. Comparison of Three Graft-versus-Host Disease Prophylaxis Strategies after T Cell-Replete Haploidentical Hematopoietic Transplantation: Tacrolimus versus Calcineurin Inhibitors plus Mycophenolate Mofetil versus Sirolimus plus Mycophenolate Mofetil. Transplantation And Cellular Therapy. 2024; 30(10)DOI:10.1016/j.jtct.2024.07.027. PMID:39116938. IF:4.400(Q1/1D).
01/10/2024
THE IMPACT OF INDIVIDUAL COMORBIDITIES ON NRM RISK FOLLOWING PTCY BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN ALWP EBMT STUDY
Spyridonidis, A, Labopin, M, Savani, B, Kulagin, A, Blaise, D, Versluis, J, Sica, S, Raiola, AM, Vydra, J, Choi, G, Rovira, M, Kwon, M, Sanz, J, It la-Remes, M, Borne, PV, Martino, R, Koc, Y, Brissot, E, Nagler, A, Mohty, M, Ciceri, F. THE IMPACT OF INDIVIDUAL COMORBIDITIES ON NRM RISK FOLLOWING PTCY BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: AN ALWP EBMT STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
DELAYED ADMINISTRATION OF IXAZOMIB AS PROPHYLAXIS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Serrano, JD, Corral, LL, Valc rcel, D, Sierra, J, Ferra-Coll, C, Velazquez, TC, Dom nguez, FM, Le n, RJ, Ortega, JLR, Go i, CB, L pez, EP, Mart nez, AC, Cadenas, IG, Sim n, JAP. DELAYED ADMINISTRATION OF IXAZOMIB AS PROPHYLAXIS FOR CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT
Gagelmann, N, De Witte, M, Peczynski, C, Boreland, W, Broers, A, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Byrne, J, Bethge, W, Maertens, J, St lzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kr ger, N, Corradini, P, Finazzi, MC, Corral, L, Villar, S, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY
G mez, VE, Corral, LL, Mahillo, BA, Mellado, PA, Dom nguez, FMM, G mez, MA, Cant , PA, G mez, JM, Ochando, MT, Borrego, AB, Pinedo, LG, Ripa, MTZ, Vicent, MG, Vallejos, AB, Izquierdo, I, Cadenas, IG, Velao, SR, Musseti, A, Giro, EC, Moraleda, PP, Pascual, GO, Sierra, PAG, Garc a, L, Guti rrez, VG, P rez-Sim n, JA. RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC)
Salas, MQ, Solano, MT, Baile-Gonz lez, M, Acera-G mez, M, Fox, L, del Mar P rez-Artigas, M, Santamar a, A, Quintela-Gonz lez, MDC, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Gonz lez, SR, Mussetti, A, Lavilla, E, L pez-Marin, J, Cedillo, A, Bento, L, Sureda, A. FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY
Fern ndez-Barge, T, Dom nguez-Garcia, JJ, Escamilla, MS, Caballer, JS, Chorao, P, Boluda, JCH, Velao, SR, Cadenas, IG, Bufarull, RM, Estefania, RC, Alexandre, IF, Pe a, AG, Garc a, AT, Ruiz, RG, Luis, SF, San Miguel, EMO, Ara jo, MC, Pell n, SGD, Rodr guez, MAB. OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
FRAILTY SYNDROME IN ADULTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-CT)
Salas, MQ, Solano, MT, Baile-Gonzalez, M, Acera-G mez, M, Fox, L, Perez-Artigas, MD, Santamar a, A, Quintela-Gonz lez, MD, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Rodr guez-Gonz lez, S, Mussetti, A, Abuin-Blanco, A, Lopez-Mar n, J, Filarerro, S, Bento, L, Sureda, A. FRAILTY SYNDROME IN ADULTS UNDERGOING AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-CT). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024
Assessment of Alinity s Chagas® as a Primary Diagnostic Test for Chronic Chagas Disease in a Non-Endemic Area of Europe (Barcelona, Spain)
Abras, A, Ballart, C, Fernández-Arévalo, A, Llovet, T, Gállego, M, Muñoz, C. Assessment of Alinity s Chagas® as a Primary Diagnostic Test for Chronic Chagas Disease in a Non-Endemic Area of Europe (Barcelona, Spain). Life-Basel. 2024; 14(10)DOI:10.3390/life14101278. PMID:39459578. IF:3.400(Q1/3D).
01/10/2024
Assessing the Impact of the Way of Saint James on Psychological Distress and Subjective Well-being: The Ultreya Study
Feliu-Soler, A, Royuela-Colomer, E, Navarrete, J, Jorgensen, NN, Mariño, M, Demarzo, M, Soler, J, García-Campayo, J, Montero-Marín, J, Luciano, JV. Assessing the Impact of the Way of Saint James on Psychological Distress and Subjective Well-being: The Ultreya Study. Journal of Happiness Studies. 2024; 25(7)DOI:10.1007/s10902-024-00820-0. PMID:. IF:3.300(Q1/1D).
01/10/2024
Context matters: the evolving use of biomarkers in Alzheimer's disease care
Fortea, J. Context matters: the evolving use of biomarkers in Alzheimer's disease care. EBioMedicine. 2024; 108DOI:10.1016/j.ebiom.2024.105387. PMID:39366842. IF:10.800(Q1/1D).
01/10/2024
Blood-based multivariate methylation risk score for cognitive impairment and dementia
Koetsier, J, Cavill, R, Reijnders, R, Harvey, J, Homann, J, Kouhsar, M, Deckers, K, Kohler, S, Eijssen, LMT, van den Hove, DLA, Demuth, I, Düzel, S, Smith, RG, Smith, AR, Burrage, J, Walker, EM, Shireby, G, Hannon, E, Dempster, E, Frayling, T, Mill, J, Dobricic, V, Johannsen, P, Wittig, M, Franke, A, Vandenberghe, R, Schaeverbeke, J, Freund-Levi, Y, Frölich, L, Scheltens, P, Teunissen, CE, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Engelborghs, S, de Roeck, E, Martinez-Lage, P, Tainta, M, Lleó, A, Sala, I, Popp, J, Peyratout, G, Verhey, F, Tsolaki, M, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Vos, SJB, Lovestone, S, Visser, PJ, Lill, CM, Bertram, L, Lunnon, K, Pishva, E. Blood-based multivariate methylation risk score for cognitive impairment and dementia. ALZHEIMERS & DEMENTIA. 2024; 20(10)DOI:10.1002/alz.14061. PMID:39193899. IF:11.100(Q1/1D).
01/10/2024
Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study
Smith, RG, Pishva, E, Kouhsar, M, Imm, J, Dobricic, V, Johannsen, P, Wittig, M, Franke, A, Vandenberghe, R, Schaeverbeke, J, Freund-Levi, Y, Frölich, L, Scheltens, P, Teunissen, CE, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Engelborghs, S, de Roeck, E, Martinez-Lage, P, Altuna, M, Tainta, M, Lleó, A, Sala, I, Popp, J, Peyratout, G, Winchester, L, Nevado-Holgado, A, Verhey, F, Tsolaki, M, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Vos, SJB, Lovestone, S, Visser, PJ, Bertram, L, Lunnon, K. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study. ALZHEIMERS & DEMENTIA. 2024; 20(10)DOI:10.1002/alz.14098. PMID:39193893. IF:11.100(Q1/1D).
01/10/2024
Impact of an emergency department nurse training intervention on the adequacy of thromboprophylaxis for venous thromboembolism: the PROTESU III study
Díaz, CR, Hernández, SJ, Chaib, FB, Polo, LL, Torrecillas, LG, Ayaso, MC, Abanto, AIC, García, JP, Gamito, GM, Jiménez, D, Lecumberri, R, Artacho, PR. Impact of an emergency department nurse training intervention on the adequacy of thromboprophylaxis for venous thromboembolism: the PROTESU III study. EMERGENCIAS. 2024; 36(5)DOI:10.55633/s3me/080.2024. PMID:39364989. IF:6.300(Q1/1D).
01/10/2024
Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis
Augustin, M, Gottlieb, AB, Lebwohl, M, Pinter, A, Warren, RB, Puig, L, Warham, R, Lambert, J, Wiegratz, S, Szilagyi, B, Blauvelt, A. Complete Skin Clearance is Associated with the Greatest Benefits to Health-Related Quality of Life and Perceived Symptoms for Patients with Psoriasis. Dermatology and Therapy. 2024; 14(10)DOI:10.1007/s13555-024-01261-6. PMID:39285121. IF:4.200(Q1/1D).
01/10/2024
Treatment of functionally nonsignificant vulnerable plaques in multivessel STEMI: design of the VULNERABLE trial
Gomez-Lara, J, Lopez-Palop, R, Rumiz, E, Jurado-Roman, A, Gomez-Menchero, A, Valencia, J, Fernandez, E, Ramirez, LRG, Brugaletta, S, Millan, R, Cortes, C, Tejedor, P, Gutierrez-Barrios, A, Flores, X, Cid-alvarez, AB, Garcia-Blas, S, Garcia-Camarero, T, Vicente, JAL, Vaquerizo, B, Soriano, JGC, Caballero, J, Piris, RMC, Sanchez-Elvira, G, Oyarzabal, L, Pernigotti, A, Tramullas, A, Antuna, P, Rodriguez-Leor, O, Ojeda, S, Rossello, X, Gomez-Hospital, JA, Bermejo, J, Garcia-Garcia, HM, Prado, APD, Gutierrez-Ibanes, E. Treatment of functionally nonsignificant vulnerable plaques in multivessel STEMI: design of the VULNERABLE trial. REC, interventional cardiology. 2024; 6(4)DOI:10.24875/RECIC.M24000468. PMID:. IF:(Q/D).
01/10/2024
PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia.
Borràs C, Canyelles M, Girona J, Ibarretxe D, Santos D, Revilla G, Llorente-Cortes V, Rotllan N, Kovanen PT, Jauhiainen M, Lee-Rueckert M, Masana L, Arrieta F, Martínez-Botas J, Gómez-Coronado D, Ribalta J, Tondo M, Blanco-Vaca F, Escolà-Gil JC. PCSK9 Antibodies Treatment Specifically Enhances the Macrophage-specific Reverse Cholesterol Transport Pathway in Heterozygous Familial Hypercholesterolemia.. Jacc-Basic To Translational Science. 2024; 9(10)DOI:10.1016/j.jacbts.2024.06.008. PMID:39534644. IF:(Q/D).
01/10/2024
Effect of Moderate Beer Intake on the Lipid Composition of Human Red Blood Cell Membranes
López-Yerena, A, Muñoz-García, N, Villaplana, VD, Padro, T, Badimon, L. Effect of Moderate Beer Intake on the Lipid Composition of Human Red Blood Cell Membranes. Nutrients. 2024; 16(20)DOI:10.3390/nu16203541. PMID:39458535. IF:5.000(Q1/2D).
30/09/2024
Prevalence of potentially inappropriate medications and prescription dynamics in elderly hospitalized patients in Spain
Puig, T, Leache, L, González-Senac, NM, Carreras, E, Gutiérrez-Valencia, M, Losa, L, Revuelta-Herrero, JL, Marrero-Alvarez, P, de Miguel, M, Arredondo, AA, Aranguren, A, Vilariño, A, Ruiz, VE, Fernández, I, Bilbao, J, González-Guerrero, C, del Pino, B, Garin, N. Prevalence of potentially inappropriate medications and prescription dynamics in elderly hospitalized patients in Spain. BMC Geriatrics. 2024; 24(1)DOI:10.1186/s12877-024-05308-3. PMID:39350081. IF:3.800(Q2/4D).
30/09/2024
Consensus statement addressing controversies and guidelines on pediatric urolithiasis (vol 42, 473, 2024)
Güven, S, Tokas, T, Tozsin, A, Haid, B, Lendvay, TS, Silay, S, Mohan, VC, Cansino, JR, Saulat, S, Straub, M, Tur, AB, Akguel, B, Samotyjek, J, Lusuardi, L, Ferretti, S, Cavdar, OF, Ortner, G, Sultan, S, Choong, S, Micali, S, Saltirov, I, Sezer, A, Netsch, C, de Lorenzis, E, Cakir, OO, Zeng, G, Gozen, AS, Bianchi, G, Jurkiewicz, B, Knoll, T, Rassweiler, J, Ahmed, K, Sarica, K. Consensus statement addressing controversies and guidelines on pediatric urolithiasis (vol 42, 473, 2024). WORLD JOURNAL OF UROLOGY. 2024; 42(1)DOI:10.1007/s00345-024-05282-w. PMID:39348069. IF:2.900(Q2/3D).
28/09/2024
Assessing and correcting neighborhood socioeconomic spatial sampling biases in citizen science mosquito data collection
Padilla-Pozo, A, Bartumeus, F, Montalvo, T, Sanpera-Calbet, I, Valsecchi, A, Palmer, JRB. Assessing and correcting neighborhood socioeconomic spatial sampling biases in citizen science mosquito data collection. Scientific Reports. 2024; 14(1)DOI:10.1038/s41598-024-73416-6. PMID:39341898. IF:3.900(Q1/2D).
27/09/2024
Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer
Liu, K, Nicoletti, R, Zhao, HD, Chen, X, Wu, HW, Leung, CH, D'Andrea, D, Laukhtina, E, Soria, F, Gallioli, A, Wroclawski, ML, Castellani, D, Gauhar, V, Rivas, JG, Enikeev, D, Gontero, P, Shariat, SF, Chiu, PKF, Ng, CF, Teoh, JYC. Young age and adequate BCG are key factors for optimal BCG treatment efficacy in non-muscle-invasive bladder cancer. WORLD JOURNAL OF UROLOGY. 2024; 42(1)DOI:10.1007/s00345-024-05218-4. PMID:39331198. IF:2.900(Q2/3D).
27/09/2024
EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake
Pirri, D, Tian, SY, Tardajos-Ayllon, B, Irving, SE, Donati, F, Allen, SP, Mammoto, T, Vilahur, G, Kabir, L, Bennett, J, Rasool, Y, Pericleous, C, Mazzei, G, McAllan, L, Scott, WR, Koestler, T, Zingg, U, Birdsey, GM, Miller, CL, Schenkel, T, Chambers, EV, Dunning, MJ, Serbanovic-Canic, J, Botrè, F, Mammoto, A, Xu, SW, Osto, E, Han, WP, Fragiadaki, M, Evans, PC. EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake. CIRCULATION RESEARCH. 2024; 135(8)DOI:10.1161/CIRCRESAHA.123.324054. PMID:39234692. IF:16.200(Q1/1D).
27/09/2024
Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations
Kulisevsky, J, Ferraz, HB, Suppa, A, Reichmann, H. Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations. EUROPEAN NEUROLOGY. 2024; 87(5-6)DOI:10.1159/000541362. PMID:39342935. IF:2.400(Q3/6D).
25/09/2024
Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma
Katayama, S, Pradere, B, Grossman, NC, Potretzke, AM, Boorjian, SA, Ghoreifi, A, Daneshmand, S, Djaladat, H, Sfakianos, JP, Mari, A, Khene, ZE, D'andrea, D, Hayakawa, N, Fujita, K, Heindenreich, A, Raman, JD, Roumiguié, M, Abdollah, F, Breda, A, Fontana, M, Rouprêt, M, Margulis, V, Karakiewicz, PI, Araki, M, Nasu, Y, Shariat, SF. Clinical Significance of Tumor Location for Ureteroscopic Tumor Grading in Upper Tract Urothelial Carcinoma. JOURNAL OF ENDOUROLOGY. 2024; 38(11)DOI:10.1089/end.2024.0335. PMID:39264866. IF:2.800(Q2/3D).
24/09/2024
Escalating costs of innovative medicines: perspective and proposals
Vallano, A, Pontes, C. Escalating costs of innovative medicines: perspective and proposals. Frontiers in Public Health. 2024; 12DOI:10.3389/fpubh.2024.1449707. PMID:39381757. IF:3.400(Q1/2D).
24/09/2024
ESGE/ESGO/SERGS consensus statement on surgical steps in minimally invasive surgery in gynecologic oncology: transperitoneal and extraperitioneal approach for paraaortic lymphadenectomy
Rovira, R, Mereu, L, Planchamp, F, Falconer, H, El-Balat, A, Barahona, M, Fagotti, A, Querleu, D, Taskiran, C. ESGE/ESGO/SERGS consensus statement on surgical steps in minimally invasive surgery in gynecologic oncology: transperitoneal and extraperitioneal approach for paraaortic lymphadenectomy. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2024; DOI:10.1136/ijgc-2024-005796. PMID:39317443. IF:4.700(Q1/1D).
24/09/2024
An international film dosimetry intercomparison to establish a multi-center audit framework
Beveridge, S, Alves, A, Hussein, M, Clark, CH, Jornet, N, Viegas, CCB, Reniers, B, Alvarez, PE, Azangwe, G, Chelminski, K, Dimitriadis, A, Kazantsev, P, Swamidas, J. An international film dosimetry intercomparison to establish a multi-center audit framework. MEDICAL PHYSICS. 2024; 51(12)DOI:10.1002/mp.17428. PMID:39316455. IF:3.200(Q1/3D).
23/09/2024
Alzheimer Dementia Among Individuals With Down Syndrome
Rubenstein, E, Tewolde, S, Michals, A, Weuve, J, Fortea, J, Fox, MP, Jimenez, MP, Scott, A, Tripodis, Y, Skotko, BG. Alzheimer Dementia Among Individuals With Down Syndrome. JAMA Network Open. 2024; 7(9)DOI:10.1001/jamanetworkopen.2024.35018. PMID:39312235. IF:9.700(Q1/1D).
23/09/2024
Household Economic Hardship and Child Mental Health: The Mediating Role of Parents' Mental Distress in a Southern European City
Bartoll-Roca, X, Cano, GS, Albaladejo, MC, Pérez, K. Household Economic Hardship and Child Mental Health: The Mediating Role of Parents' Mental Distress in a Southern European City. SOCIAL INDICATORS RESEARCH. 2024; 175(1)DOI:10.1007/s11205-024-03428-2. PMID:. IF:2.800(Q1/2D).